Autoimmune Encephalitis natural history, complications and prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Autoimmune encephalitis is potentially life-threatening, but substantial recovery is possible with appropriate treatment. The course varies with antibody subtype, associated neoplasm, attack severity, and treatment timing. Important complications include seizures, autonomic instability, respiratory compromise, and persistent cognitive or psychiatric impairment.[1]
Functional independence does not necessarily indicate complete recovery from autoimmune encephalitis. Cognitive, emotional, sleep, and energy-related difficulties may persist after apparent neurological improvement.[2]
Natural History
Autoimmune encephalitis usually develops over days to weeks, with progression over less than 3 months in typical presentations. Memory impairment, altered mental status, psychiatric symptoms, and seizures may precede more extensive neurological dysfunction. The sequence is not identical in every subtype.[3] Leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) antibody disease may have a more insidious course.[4]
- Progression without effective treatment: Severe disease can progress to refractory seizures, impaired consciousness, autonomic instability, respiratory failure, and death. Published treatment cohorts should not be interpreted as providing an untreated progression or survival rate.[4]
- N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis: Psychiatric or cognitive symptoms may be followed by speech dysfunction, seizures, dyskinesias, reduced consciousness, autonomic dysfunction, or central hypoventilation. Not every patient develops all manifestations.[3]
- LGI1 antibody encephalitis: Faciobrachial dystonic seizures can precede cognitive impairment. An observational study linked earlier immunotherapy and seizure cessation with reduced progression to cognitive impairment.[5]
- Recovery or recurrence: After the acute episode, patients may improve, retain residual deficits, or experience relapse. Temporary fluctuations in cognition or seizures do not necessarily represent renewed autoimmune inflammation.[6]
Complications
Acute neurological and systemic complications
Autoimmune encephalitis can cause the following acute complications:
- Seizures and status epilepticus: Recurrent seizures may progress to refractory status epilepticus requiring intensive care.
- Dysautonomia: Blood pressure and heart-rate instability, severe arrhythmias, and temperature dysregulation may occur.
- Respiratory compromise: Central hypoventilation or associated neurological dysfunction may necessitate mechanical ventilation.
- Reduced consciousness: Severe encephalopathy may progress to coma.
- Hyponatremia: Particularly associated with LGI1 antibody encephalitis, often through inappropriate antidiuretic hormone secretion.[4]
- Complications of prolonged critical illness: Aspiration, hospital-acquired infection, venous thromboembolism, nutritional difficulties, and deconditioning may add to neurological disability.[6]
Long-term neurological and psychosocial complications
Autoimmune encephalitis survivors may experience persistent problems despite functional independence:
- Cognitive impairment: Memory, attention, language, processing speed, and executive function may remain impaired.
- Psychiatric symptoms: Depression, anxiety, emotional lability, behavioral change, or trauma-related symptoms may persist.
- Fatigue and sleep disturbance: Reduced energy, insomnia, or excessive sleepiness can impair daily functioning.
- Participation restrictions: Difficulties returning to education, employment, independent living, and social activities can persist; family and caregiver burden may be substantial.[2]
- Persistent seizures or epilepsy: Chronic, sometimes drug-resistant epilepsy can persist after the acute episode; risk varies by subtype.[7]
- Other residual neurological deficits: Movement, coordination, brainstem, or autonomic symptoms may remain after the acute illness.[7]
Treatment-related complications
Autoimmune encephalitis treatment can produce adverse effects that require monitoring:
- Corticosteroids: Infection, hyperglycemia, hypertension, neuropsychiatric effects, and, with prolonged exposure, osteoporosis and other metabolic complications.
- Prolonged immunosuppression: Serious or opportunistic infections and infection reactivation may occur; cyclophosphamide additionally carries infertility risk.
- Antipsychotic medication: Drug-induced movement disorders, rhabdomyolysis, or neuroleptic malignant syndrome can occur, particularly with potent dopamine-blocking agents.[1]
- Intravenous immunoglobulin: Thromboembolic events and volume-related worsening of hyponatremia are recognized concerns.
- Plasma exchange: Bleeding, hemodynamic effects from volume shifts, and central venous catheter complications can occur.[4]
Prognosis
Functional and cognitive recovery
Autoimmune encephalitis outcomes vary by subtype. In a 2025 adult referral-center cohort, 138 of 172 patients with recovery data (80%) achieved functional independence (modified Rankin Scale [mRS] ≤2), which does not imply complete recovery.[7]
- NMDAR antibody encephalitis: In the international cohort used to develop the updated anti-NMDAR Encephalitis One-year functional Status score (NEOS2), 517 of 644 patients assessed at 1 year (80%) had an mRS score of 2 or less.[8]
- Prolonged cognitive recovery: A 2024 study of 92 patients with NMDAR antibody encephalitis found improvement extending to approximately 3 years. Among 44 assessed beyond 36 months, 34% had impairment in at least one cognitive domain, despite generally favorable mRS outcomes. Difficulties returning to work or education were also common.[9]
- Paraneoplastic disease: Encephalitis associated with classical intracellular neuronal antibodies may be less responsive to immunotherapy. Neurological injury and the underlying cancer both influence outcome; this pattern is not universal.[1]
- Antibody-negative disease: Recovery is possible, but published outcome data are limited and depend on the clinical syndrome and cohort studied.[7]
The 2026 United Kingdom (UK) guideline emphasizes that long-term deficits can be underestimated at discharge. Follow-up should assess cognition, mental health, sleep, seizures, and rehabilitation needs, alongside functional independence.[2]
Relapse
Autoimmune encephalitis relapse risk depends on subtype, treatment, and follow-up duration. The following are cohort-specific estimates and are not directly comparable:
| Subtype | Published estimate | Interpretation |
|---|---|---|
| NMDAR antibody encephalitis | Approximately 12% risk within 2 years in a large observational cohort.[10] | Relapses were often milder than the initial episode.[10] |
| LGI1 antibody encephalitis | 12 of 104 patients (11.5%) relapsed in a 2026 multicenter cohort requiring at least 24 months of follow-up.[11] | This estimate reflects that cohort's treatment practices and observation period. |
| CASPR2 antibody disease | 60% experienced relapse in a 44-patient cohort with median follow-up of 55 months, reported in 2026.[12] | The study concerns the broader CASPR2 disease spectrum, including central and peripheral manifestations, rather than an encephalitis-only population. |
New or worsening symptoms require assessment for relapse and alternative explanations. Residual symptom fluctuations or breakthrough seizures alone do not establish recurrent inflammation; magnetic resonance imaging (MRI), electroencephalography (EEG), or cerebrospinal fluid findings may help support the diagnosis.[6]
Mortality
Autoimmune encephalitis mortality depends on subtype, severity, associated cancer, complications, and follow-up period. Illustrative cohort findings include:
- NMDAR antibody encephalitis: In the landmark treatment cohort, 30 of 501 patients with assessable outcomes died during the first 24 months, approximately 6%. Most received immunotherapy or tumor removal.[10]
- Mixed adult autoimmune encephalitis: A 2025 referral-center cohort recorded 20 deaths among 182 patients (11%) over variable follow-up, with a median follow-up of 44 months. Causes included neurological deterioration, cancer progression, and infection.[7]
These figures should not be presented as a single mortality rate for all autoimmune encephalitis or as an estimate of untreated survival.
Factors associated with outcome
Autoimmune encephalitis prognosis varies with subtype, malignancy, attack severity, and treatment timing; these associations do not determine individual recovery.[1]
- NMDAR-specific prediction: NEOS2 was developed and validated in an international cohort of 702 patients. Its predictors include age, treatment delay, movement disorders, intensive care requirement, and cerebrospinal fluid leukocyte count. It estimates functional outcome in NMDAR antibody encephalitis and should not be generalized to other autoimmune encephalitis subtypes or interpreted as a complete measure of cognitive recovery.[8]
- Persistent disability: Severe attacks and paraneoplastic disease were associated with poorer functional recovery in the 2025 adult cohort; delayed immunotherapy and severe initial cognitive deficits were associated with post-encephalitic dementia.[7]
- LGI1-specific observations: Hyponatremia at diagnosis was associated with relapse and poorer functional outcome in the 2026 LGI1 cohort. These findings require further prospective validation.[11]
References
- ↑ 1.0 1.1 1.2 1.3 Hahn C, Budhram A, Alikhani K; et al. (2024). "Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults". Canadian Journal of Neurological Sciences. 51 (6): 734–754. doi:10.1017/cjn.2024.16. PMID 38312020 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 Michael BD, Huang Y, McKeever S; et al. (2026). "Management of suspected infectious and autoimmune encephalitis in adults – National Guidelines from the United Kingdom Joint Societies". Journal of Infection: 106873. doi:10.1016/j.jinf.2026.106873. PMID 42863638 Check
|pmid=value (help). - ↑ 3.0 3.1 Graus F, Titulaer MJ, Balu R; et al. (2016). "A clinical approach to diagnosis of autoimmune encephalitis". The Lancet Neurology. 15 (4): 391–404. doi:10.1016/S1474-4422(15)00401-9. PMID 26906964.
- ↑ 4.0 4.1 4.2 4.3 Abboud H, Probasco JC, Irani S; et al. (2021). "Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management". Journal of Neurology, Neurosurgery & Psychiatry. 92 (7): 757–768. doi:10.1136/jnnp-2020-325300. PMID 33649022 Check
|pmid=value (help). - ↑ Thompson J, Bi M, Murchison AG; et al. (2018). "The importance of early immunotherapy in patients with faciobrachial dystonic seizures". Brain. 141 (2): 348–356. doi:10.1093/brain/awx323. PMID 29272336.
- ↑ 6.0 6.1 6.2 Abboud H, Probasco JC, Irani S; et al. (2021). "Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management". Journal of Neurology, Neurosurgery & Psychiatry. 92 (8): 897–907. doi:10.1136/jnnp-2020-325302. PMID 33649021 Check
|pmid=value (help). - ↑ 7.0 7.1 7.2 7.3 7.4 7.5 Thakolwiboon S, Gilligan M, Orozco E; et al. (2025). "Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae". Journal of Neurology, Neurosurgery & Psychiatry. 96 (8): 736–743. doi:10.1136/jnnp-2024-334957. PMID 39832911 Check
|pmid=value (help). - ↑ 8.0 8.1 Brenner J, Bastiaansen AEM, Guasp M; et al. (2026). "Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study". The Lancet Regional Health – Europe. 62: 101562. doi:10.1016/j.lanepe.2025.101562. PMID 41488792 Check
|pmid=value (help). - ↑ Brenner J, Ruhe CJ, Kulderij I; et al. (2024). "Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis". Neurology. 103 (12): e210109. doi:10.1212/WNL.0000000000210109. PMID 39566012 Check
|pmid=value (help). - ↑ 10.0 10.1 10.2 Titulaer MJ, McCracken L, Gabilondo I; et al. (2013). "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study". The Lancet Neurology. 12 (2): 157–165. doi:10.1016/S1474-4422(12)70310-1. PMID 23290630.
- ↑ 11.0 11.1 Shen CH, Jin B, Du Y; et al. (2026). "Relapse risk and functional outcomes in anti-LGI1 encephalitis: A multicenter retrospective analysis". Therapeutic Advances in Neurological Disorders. 19: 17562864261477197. doi:10.1177/17562864261477197. PMID 42572567 Check
|pmid=value (help). - ↑ Brand T, Franken SC, Vermeiren MR; et al. (2026). "High Relapse Rate in Anti-CASPR2 Disease: Implications for Prolonged Immunotherapy". Neurology: Neuroimmunology & Neuroinflammation. 13 (1): e200524. doi:10.1212/NXI.0000000000200524. PMID 41401401 Check
|pmid=value (help).